These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Transdermal scopolamine in the prevention of motion sickness at sea. Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021 [TBL] [Abstract][Full Text] [Related]
4. Further experiments on the prevention of motion sickness. GLASER EM; HERVEY GR Lancet; 1952 Mar; 1(6706):490-2. PubMed ID: 14898786 [No Abstract] [Full Text] [Related]
6. Theory of antimotion sickness drug mechanisms. Wood CD; Graybiel A Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925 [No Abstract] [Full Text] [Related]
7. Modafinil as a potential motion sickness countermeasure. Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573 [TBL] [Abstract][Full Text] [Related]
8. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors. Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Golding JF; Stott JR Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824 [TBL] [Abstract][Full Text] [Related]
10. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine. Patel PN; Ezzo DC Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085 [TBL] [Abstract][Full Text] [Related]
11. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Gil A; Nachum Z; Tal D; Shupak A Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622 [TBL] [Abstract][Full Text] [Related]
12. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Nachum Z; Shupak A; Gordon CR Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539 [TBL] [Abstract][Full Text] [Related]
13. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820 [TBL] [Abstract][Full Text] [Related]
14. Statement on motion sickness. Committee to Advise on Tropical Medicine and Travel Can Commun Dis Rep; 2003 Nov; 29():1-12. PubMed ID: 14655530 [No Abstract] [Full Text] [Related]
15. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Klöcker N; Hanschke W; Toussaint S; Verse T Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908 [TBL] [Abstract][Full Text] [Related]
16. The pharmacologic absis for the control of motion sickness by drugs. Brand J Pharmacol Physicians; 1968 Mar; 2(3):1-5. PubMed ID: 4384429 [No Abstract] [Full Text] [Related]
18. Transderm Scop patches for prevention of motion sickness. Johnson P; Hansen D; Matarazzo D; Petterson L; Swisher C; Trappolini A N Engl J Med; 1984 Aug; 311(7):468-9. PubMed ID: 6749195 [No Abstract] [Full Text] [Related]
19. Fixed dilated pupil in the long distance traveller. Dunlop IS Med J Aust; 1995 Jan; 162(1):56. PubMed ID: 7845307 [No Abstract] [Full Text] [Related]
20. Motion illness. Hervey GR Trans Med Soc Lond; 1984-1985; 101():14-20. PubMed ID: 6152833 [No Abstract] [Full Text] [Related] [Next] [New Search]